Actinomycin

Phase 1Small molecule

HH. Lee Moffitt Cancer Center and Research Institute

Actinomycin is one of 15 small molecule programs targeting Metastatic Ewing Sarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Ewing SarcomaRecruiting

Metastatic Ewing SarcomaPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Metastatic Ewing Sarcoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

2 2

Oncovin

Eli Lilly

Phase 3

2 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 4

Vepesid

AAvyxa

Phase 3

2 5

Ifex

BBaxter Healthcare Corporation

Phase 3

2 6

Adriamycin

GGynecologic Oncology Group

Phase 3

1 7

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

1 8

Oncovin

EEastern Cooperative Oncology Group

Phase 3

1 9

Ganitumab

Amgen

Phase 3

1 10

Camptosar

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

Metastatic Ewing Sarcoma

NCT07194044

Clinical

Trials by Indication[1]

Metastatic Ewing Sarcoma1 trial

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT07194044·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Actinomycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actinomycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actinomycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — H. Lee Moffitt Cancer Center and Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HH. Lee Moffitt Cancer Center and Research Institute

Actinomycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Metastatic Ewing Sarcoma1 trial

References

Drug Info

Quick Facts

Related News